scispace - formally typeset
D

Dae Hwan Kang

Researcher at Pusan National University

Publications -  267
Citations -  4906

Dae Hwan Kang is an academic researcher from Pusan National University. The author has contributed to research in topics: Stent & Endoscopic mucosal resection. The author has an hindex of 34, co-authored 258 publications receiving 4198 citations. Previous affiliations of Dae Hwan Kang include New Generation University College.

Papers
More filters
Journal ArticleDOI

Endoscopic sphincterotomy plus large-balloon dilation versus endoscopic sphincterotomy for removal of bile-duct stones

TL;DR: In this article, the authors compared the effect of EST plus LBD with that of EST alone in terms of successful bile duct stone removal and complications such as pancreatitis and bleeding.
Journal ArticleDOI

Biliary MR Imaging with Gd-EOB-DTPA and Its Clinical Applications

TL;DR: The hepatocyte-specific contrast agent gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) was developed to improve the detection and characterization of focal liver lesions at magnetic resonance (MR) imaging.
Journal ArticleDOI

Biocompatible Poly(2-hydroxyethyl methacrylate)-b-poly(l- histidine) Hybrid Materials for pH-Sensitive Intracellular Anticancer Drug Delivery

TL;DR: The p(HEMA)‐b‐p(His) hybrid materials are capable of self‐assembling into nanomicelles and effectively encapsulating the chemotherapeutic agent Dox, which allows them to serve as suitable carriers of drug molecules for tumor targeting.
Journal ArticleDOI

Dual Stimuli-Responsive Poly(N-isopropylacrylamide)-b-poly(l-histidine) Chimeric Materials for the Controlled Delivery of Doxorubicin into Liver Carcinoma

TL;DR: The new chimeric materials synthesized by NIPAM display tunable properties that can make them useful for a molecular switching device and controlled drug delivery applications needing responses to temperature and pH for the improvement of cancer chemotherapy.
Journal ArticleDOI

Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans

TL;DR: The goal of this study was to demonstrate induction of functional anticancer immunity that can lyse target cancer cells in humans, and it was determined that patients with the longest survival duration had the highest CDC activity, and identified candidate target tumor cell antigens.